UBS Group AG - APELLIS PHARMACEUTICALS INC ownership

APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 213 filers reported holding APELLIS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.31 and the average weighting 0.5%.

Quarter-by-quarter ownership
UBS Group AG ownership history of APELLIS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$147,063
-98.9%
3,866
-97.4%
0.00%
-100.0%
Q2 2023$13,332,940
+93.7%
146,355
+40.2%
0.01%
+66.7%
Q1 2023$6,883,850
+0.9%
104,364
-20.9%
0.00%0.0%
Q4 2022$6,820,393
+231.2%
131,897
+337.6%
0.00%
Q3 2022$2,059,000
-36.9%
30,139
-58.2%
0.00%
-100.0%
Q2 2022$3,262,000
-44.0%
72,123
-37.1%
0.00%
-50.0%
Q1 2022$5,825,000
+12.6%
114,649
+4.8%
0.00%
+100.0%
Q4 2021$5,172,000
-20.3%
109,387
-44.4%
0.00%
-50.0%
Q3 2021$6,489,000
+82.9%
196,882
+250.8%
0.00%
+100.0%
Q2 2021$3,547,000
+606.6%
56,119
+379.9%
0.00%
Q1 2021$502,000
+750.8%
11,694
+1034.2%
0.00%
Q4 2020$59,000
+555.6%
1,031
+251.9%
0.00%
Q3 2020$9,000
-90.2%
293
-89.6%
0.00%
Q2 2020$92,000
-73.5%
2,820
-78.2%
0.00%
Q1 2020$347,000
-59.8%
12,938
-54.1%
0.00%
Q4 2019$863,000
+16.2%
28,171
-8.7%
0.00%
Q3 2019$743,000
-37.0%
30,852
-33.7%
0.00%
Q2 2019$1,179,000
+547.8%
46,526
+397.6%
0.00%
Q1 2019$182,000
-78.5%
9,351
-85.4%
0.00%
Q4 2018$847,000
+82.9%
64,179
+146.5%
0.00%
Q3 2018$463,000
+223.8%
26,033
+301.2%
0.00%
Q2 2018$143,000
+24.3%
6,489
+25.0%
0.00%
Q1 2018$115,000
+35.3%
5,191
+33.0%
0.00%
Q4 2017$85,0003,9030.00%
Other shareholders
APELLIS PHARMACEUTICALS INC shareholders Q2 2022
NameSharesValueWeighting ↓
AJU IB Investment Co., Ltd. 1,114,962$63,776,00024.13%
Octagon Capital Advisors LP 548,374$31,367,00010.87%
Ghost Tree Capital, LLC 325,000$18,590,0004.14%
Burrage Capital Management LLC 81,357$4,654,0003.55%
Aufman Associates Inc 53,642$3,068,0002.75%
ACUTA CAPITAL PARTNERS, LLC 167,054$9,555,0002.60%
Cormorant Asset Management, LP 1,866,108$106,741,0002.54%
Tri Locum Partners LP 121,409$6,945,0002.52%
venBio Partners LLC 490,471$28,055,0002.48%
HHLR ADVISORS, LTD. 5,028,289$287,618,0002.29%
View complete list of APELLIS PHARMACEUTICALS INC shareholders